Holen Sie sich die Stockscreener-App
2.64
1.49%
-0.04
Handel nachbörslich:
2.64
Schlusskurs vom Vortag:
$2.68
Offen:
$2.68
24-Stunden-Volumen:
60,402
Relative Volume:
0.20
Marktkapitalisierung:
$3.54M
Einnahmen:
$12.31M
Nettoeinkommen (Verlust:
$-5.08M
KGV:
-2.8085
EPS:
-0.94
Netto-Cashflow:
$-5.20M
1W Leistung:
-4.00%
1M Leistung:
-1.12%
6M Leistung:
-52.62%
1J Leistung:
-30.05%
1-Tages-Spanne:
$2.64
$2.75
1-Wochen-Bereich:
$2.64
$2.845
52-Wochen-Spanne:
$2.44
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Firmenname
Sonoma Pharmaceuticals Inc
Sektor
Telefon
800-759-9305
Adresse
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Vergleichen Sie SNOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.64 | 3.54M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Sonoma Pharmaceuticals Inc Aktie (SNOA) Neueste Nachrichten
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Sonoma Pharmaceuticals ends agreement with EMC Pharma - Investing.com
Merck (MRK) Stock Surges Amid Industry Layoff Trends - GuruFocus.com
Sonoma Pharmaceuticals ends agreement with EMC Pharma By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in - PharmiWeb.com
Amarin (AMRN) Stock Surges Amid Mixed Industry Performance - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of - One News Page
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Animal Wound Care Market to Exhibit a Remarkable CAGR of 7.9% - openPR
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report - GuruFocus.com
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Sonoma Pharmaceuticals gains FDA clearance for hydrogel By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Sonoma Pharmaceuticals gains FDA clearance for hydrogel - Investing.com India
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel - AccessWire
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sonoma Pharmaceuticals Inc. (SNOA) Quarterly 10-Q Report - Quartz
Sonoma Pharmaceuticals Inc (SNOA) Quarterly 10-Q Report - Quartzy
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results - AccessWire
Certain Options of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Restricted Stock Units of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Warrants of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Preferred stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Finanzdaten der Sonoma Pharmaceuticals Inc-Aktie (SNOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.58%
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):